Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Cysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.80 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL1268415 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL3320713 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL6675043 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL2233580 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL3320717 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL6028716 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL1907826 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL28436580 | 0.98 | PTGS1 (0.76) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Aspartic Acid SCHEMBL8628354 | 0.91 | PTGS1 (0.67) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Serine SCHEMBL418635 | 0.91 | PTGS1 (0.67) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 625 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118845705-A | Three-component lipid nanoparticle for nucleic acid delivery and preparation method thereof | 天津科技大学 | 2024-10-29 | — | — | CN | claimed |
| US-12103947-B2 | Methods for producing peptide thioester and peptide | GLYTECH, INC. (JP) | 2024-10-01 | — | — | US | claimed |
| EP-4399322-A1 | USE OF AT LEAST TWO VOLATILE COMPOUND PRECURSORS FOR CHARACTERISING THE ABILITY OF THE MICROORGANISMS CONTAINED IN A BIOLOGICAL SAMPLE TO RELEASE VOLATILE COMPOUNDS | Aryballe (FR) | 2024-07-17 | — | — | EP | claimed |
| EP-3930764-B1 | RENAL CLEARABLE NANOPARTICLES AS EXOGENOUS MARKERS FOR EVALUATING KIDNEY FUNCTION | UNIV TEXAS (US) | 2024-06-05 | — | — | EP | claimed |
| CN-117986219-A | Method for preparing thioglycoside from 6-aryl/alkylthio-2H-pyran-3-ketone compound | 三峡大学 | 2024-05-07 | — | — | CN | claimed |
| CN-117531020-A | Drug carrier targeting CD74+ pro-inflammatory macrophages and preparation method and application thereof | 暨南大学附属第一医院（广州华侨医院） | 2024-02-09 | — | — | CN | claimed |
| CN-117405800-A | Method for simultaneously detecting reduced biological ammonia sulfhydryl compound and oxidized biological ammonia sulfhydryl compound | 上海中医药大学 | 2024-01-16 | — | — | CN | claimed |
| US-11699530-B2 | Use of multivariate analysis to assess treatment approaches | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2023-07-11 | — | — | US | claimed |
| CN-116327971-A | Drug carrier targeting CD74+ pro-inflammatory macrophages and preparation method and application thereof | 暨南大学附属第一医院（广州华侨医院） | 2023-06-27 | — | — | CN | claimed |
| US-20230143844-A1 | NOVEL METHODS FOR PRODUCING PEPTIDE THIOESTER AND PEPTIDE | GLYTECH, INC. (JP) | 2023-05-11 | — | — | US | claimed |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | APPLIED BIOSYSTEMS, LLC | 2005-03-10 | — | — | US | claimed |
| WO-2004111072-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | APPLERA CORPORATION (US) | 2004-12-23 | — | — | WO | claimed |
| CN-1486177-A | Method and formulation for binding acetaldehyde in saliva, stomach and large intestine | ϣ�������ع�����˾ | 2004-03-31 | — | — | CN | claimed |
| EP-1339394-A1 | METHOD AND PREPARATION FOR BINDING ACETALDEHYDE IN SALIVA, STOMACH AND LARGE INTESTINE | BIOHIT OYJ (FI) | 2003-09-03 | — | — | EP | claimed |
| WO-2002036098-A1 | METHOD AND PREPARATION FOR BINDING ACETALDEHYDE IN SALIVA, STOMACH AND LARGE INTESTINE | LICENTIA LTD (FI) | 2002-05-10 | — | — | WO | claimed |
| WO-2002005785-A1 | MODULATED RELEASE THERAPEUTIC AEROSOLS | AEROPHARM TECHNOLOGY INCORPORATED (US) | 2002-01-24 | — | — | WO | claimed |
| US-5972677-A | ALLOW FOR INTERNAL INITIATION OF MRNA CAP-INDEPENDENT TRANSLATION. | Tischfield, J. | 1999-10-26 | — | — | US | claimed |
| EP-0604433-A4 | COMPOSITION AND METHOD FOR DISEASE TREATMENT. | LIFE SCIENCES TECH INC (US) | 1994-10-12 | — | — | EP | claimed |
| EP-0604433-A1 | COMPOSITION AND METHOD FOR DISEASE TREATMENT | LIFE SCIENCES' TECHNOLOGIES, INC. (US) | 1994-07-06 | — | — | EP | claimed |
| WO-1992021368-A1 | COMPOSITION AND METHOD FOR DISEASE TREATMENT | LIFE SCIENCES' TECHNOLOGIES, INC. (US) | 1992-12-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143844-A1 | NOVEL METHODS FOR PRODUCING PEPTIDE THIOESTER AND PEPTIDE | QPCT, PTMS, QPCTL | PTGS1 3503/4885SLC7A11 133/4885GLRA1 314/4885 |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | DTYMK, UNG, TPR | PTGS1 4655/4885SLC7A11 2441/4885GLRA1 3147/4885 |
| US-12103947-B2 | Methods for producing peptide thioester and peptide | QPCT, QPCTL, PTMS | PTGS1 3665/4885SLC7A11 169/4885GLRA1 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.